Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’ - Edward ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Lehigh Valley health experts discuss obesity, energy management, Medicaid changes, and GLP-1 drug trends at LVBCH’s 45th ...

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.